Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Investigation of V520 in an HIV Vaccine Proof-of-Concept Study (V520-023)

This study has been terminated.
Sponsor:
Collaborator:
HIV Vaccine Trials Network
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:
NCT00095576
First received: November 5, 2004
Last updated: October 29, 2014
Last verified: October 2014
Results First Received: July 20, 2011  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Investigator);   Primary Purpose: Prevention
Conditions: AIDS
HIV Infections
Interventions: Biological: Trivalent MRKAd5 HIV-1 gag/pol/nef (1.5x10^10 ad-vg/dose)
Drug: Comparator: placebo

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations

3000 participants were enrolled and randomized in the study. However, only 2979 received study vaccination, and are included in the started population.

V520-023 was terminated early based on findings at a planned interim analysis and subjects were encouraged to participate in the V520-030 rollover study for additional long term follow up.


Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Trivalent MRKAd5 HIV-1 Gag/Pol/Nef Participants randomized to receive three 1.0-ml intramuscular (IM) injections of Merck Trivalent Adenovirus Serotype 5 HIV-1 gag/pol/nef (MRKAd5 HIV-1 gag/pol/nef) Vaccine at a dose of 1.5x10^10 adenovirus genomes (Ad vg) per dose at Day 1, Week 4, and Week 26.
Placebo Participants randomized to receive three 1.0-ml intramuscular (IM) injections of placebo to MRKAd5 HIV-1 gag/pol/nef at Day 1, Week 4, and Week 26.

Participant Flow:   Overall Study
    Trivalent MRKAd5 HIV-1 Gag/Pol/Nef     Placebo  
STARTED     1484     1495  
VACCINATED AT VISIT 2 (Dose 1)     1484     1495  
VACCINATED AT VISIT 4 (Dose 2)     1426     1443  
VACCINATED AT VISIT 7 (Dose 3)     1328     1361  
COMPLETED     9 [1]   14 [1]
NOT COMPLETED     1475     1481  
Adverse Event                 5                 3  
Lost to Follow-up                 233                 229  
Protocol Violation                 1                 0  
Withdrawal by Subject                 34                 47  
Option to switch to a rollover study                 1097                 1099  
Site terminated                 75                 67  
Subject moved                 30                 36  
[1] Subjects not completing entire study were eligible for observational long term follow up in V520-030



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Trivalent MRKAd5 HIV-1 Gag/Pol/Nef Participants randomized to receive three 1.0-ml intramuscular (IM) injections of Merck Trivalent Adenovirus Serotype 5 HIV-1 gag/pol/nef (MRKAd5 HIV-1 gag/pol/nef) Vaccine at a dose of 1.5x10^10 adenovirus genomes (Ad vg) per dose at Day 1, Week 4, and Week 26.
Placebo Participants randomized to receive three 1.0-ml intramuscular (IM) injections of placebo to MRKAd5 HIV-1 gag/pol/nef at Day 1, Week 4, and Week 26.
Total Total of all reporting groups

Baseline Measures
    Trivalent MRKAd5 HIV-1 Gag/Pol/Nef     Placebo     Total  
Number of Participants  
[units: participants]
  1484     1495     2979  
Age  
[units: years]
Mean ± Standard Deviation
  29.9  ± 7.8     30.2  ± 8.13     30.1  ± 7.97  
Gender  
[units: participants]
     
Female     565     570     1135  
Male     919     925     1844  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Number of Participants With Clinical Adverse Experiences   [ Time Frame: Day 1 to End of Study (Week 210 for HIV uninfected participants and Week 338 for HIV infected participants) ]

2.  Primary:   Number of Participants With Laboratory Adverse Experiences   [ Time Frame: Day 1 to Week 208 ]

3.  Primary:   Number of Participants With HIV-1 Infections   [ Time Frame: Day 1 to End of Study (Week 210 for HIV uninfected participants and Week 338 for HIV infected participants) ]

4.  Primary:   HIV-1 Viral Load in Infected Participants   [ Time Frame: Day 1 to End of Study (Week 210 for HIV uninfected participants and Week 338 for HIV infected participants) ]


  Serious Adverse Events
  Hide Serious Adverse Events

Time Frame No text entered.
Additional Description No text entered.

Reporting Groups
  Description
Trivalent MRKAd5 HIV-1 Gag/Pol/Nef Participants randomized to receive three 1.0-ml intramuscular (IM) injections of Merck Trivalent Adenovirus Serotype 5 HIV-1 gag/pol/nef (MRKAd5 HIV-1 gag/pol/nef) Vaccine at a dose of 1.5x10^10 adenovirus genomes (Ad vg) per dose at Day 1, Week 4, and Week 26.
Placebo Participants randomized to receive three 1.0-ml intramuscular (IM) injections of placebo to MRKAd5 HIV-1 gag/pol/nef at Day 1, Week 4, and Week 26.

Serious Adverse Events
    Trivalent MRKAd5 HIV-1 Gag/Pol/Nef     Placebo  
Total, serious adverse events      
# participants affected / at risk     19/1484 (1.28%)     17/1495 (1.14%)  
Blood and lymphatic system disorders      
Anemia aggravated      
# participants affected / at risk     1/1484 (0.07%)     0/1495 (0.00%)  
# events     1     0  
Congenital, familial and genetic disorders      
Congenital cardiovascular anomaly      
# participants affected / at risk     0/1484 (0.00%)     2/1495 (0.13%)  
# events     0     2  
Hypoplastic left heart syndrome      
# participants affected / at risk     0/1484 (0.00%)     1/1495 (0.07%)  
# events     0     1  
Unspecified congenital anomaly of heart      
# participants affected / at risk     0/1484 (0.00%)     1/1495 (0.07%)  
# events     0     1  
Ventricular septal defect      
# participants affected / at risk     0/1484 (0.00%)     1/1495 (0.07%)  
# events     0     1  
Gastrointestinal disorders      
Acute diarrhoea      
# participants affected / at risk     0/1484 (0.00%)     1/1495 (0.07%)  
# events     0     1  
General disorders      
Fever      
# participants affected / at risk     1/1484 (0.07%)     0/1495 (0.00%)  
# events     1     0  
Rigors      
# participants affected / at risk     1/1484 (0.07%)     0/1495 (0.00%)  
# events     1     0  
Hepatobiliary disorders      
Cholecystitis acute      
# participants affected / at risk     1/1484 (0.07%)     0/1495 (0.00%)  
# events     1     0  
Immune system disorders      
Drug hypersensitivity      
# participants affected / at risk     0/1484 (0.00%)     1/1495 (0.07%)  
# events     0     1  
Infections and infestations      
Appendicitis      
# participants affected / at risk     0/1484 (0.00%)     1/1495 (0.07%)  
# events     0     1  
Gastroenteritis viral      
# participants affected / at risk     1/1484 (0.07%)     0/1495 (0.00%)  
# events     1     0  
Pulmonary tuberculosis      
# participants affected / at risk     0/1484 (0.00%)     1/1495 (0.07%)  
# events     0     1  
Shunt infection      
# participants affected / at risk     1/1484 (0.07%)     0/1495 (0.00%)  
# events     1     0  
Staphylococcal abscess      
# participants affected / at risk     1/1484 (0.07%)     0/1495 (0.00%)  
# events     1     0  
Vulval abscess      
# participants affected / at risk     1/1484 (0.07%)     0/1495 (0.00%)  
# events     1     0  
Injury, poisoning and procedural complications      
Asbestosis      
# participants affected / at risk     0/1484 (0.00%)     1/1495 (0.07%)  
# events     0     1  
Gun shot wound      
# participants affected / at risk     1/1484 (0.07%)     1/1495 (0.07%)  
# events     1     1  
Overdose      
# participants affected / at risk     1/1484 (0.07%)     0/1495 (0.00%)  
# events     1     0  
Stab wound      
# participants affected / at risk     0/1484 (0.00%)     1/1495 (0.07%)  
# events     0     1  
Traumatic brain injury      
# participants affected / at risk     1/1484 (0.07%)     0/1495 (0.00%)  
# events     1     0  
Metabolism and nutrition disorders      
Dehydration      
# participants affected / at risk     0/1484 (0.00%)     1/1495 (0.07%)  
# events     0     1  
Musculoskeletal and connective tissue disorders      
Low back pain      
# participants affected / at risk     1/1484 (0.07%)     0/1495 (0.00%)  
# events     1     0  
Musculoskeletal pain      
# participants affected / at risk     1/1484 (0.07%)     0/1495 (0.00%)  
# events     1     0  
Slipped disc      
# participants affected / at risk     1/1484 (0.07%)     0/1495 (0.00%)  
# events     1     0  
Neoplasms benign, malignant and unspecified (incl cysts and polyps)      
Gastric cancer      
# participants affected / at risk     1/1484 (0.07%)     0/1495 (0.00%)  
# events     1     0  
Uterine fibroids      
# participants affected / at risk     0/1484 (0.00%)     1/1495 (0.07%)  
# events     0     1  
Nervous system disorders      
Headache      
# participants affected / at risk     1/1484 (0.07%)     0/1495 (0.00%)  
# events     1     0  
Psychiatric disorders      
Depression      
# participants affected / at risk     1/1484 (0.07%)     1/1495 (0.07%)  
# events     1     1  
Depression aggravated      
# participants affected / at risk     0/1484 (0.00%)     1/1495 (0.07%)  
# events     0     1  
Depressive episode      
# participants affected / at risk     1/1484 (0.07%)     0/1495 (0.00%)  
# events     1     0  
Manic episode      
# participants affected / at risk     0/1484 (0.00%)     1/1495 (0.07%)  
# events     0     1  
Polysubstance dependence      
# participants affected / at risk     1/1484 (0.07%)     0/1495 (0.00%)  
# events     1     0  
Substance abuse      
# participants affected / at risk     0/1484 (0.00%)     1/1495 (0.07%)  
# events     0     1  
Suicide attempt      
# participants affected / at risk     0/1484 (0.00%)     1/1495 (0.07%)  
# events     0     1  
Renal and urinary disorders      
Kidney stone      
# participants affected / at risk     1/1484 (0.07%)     0/1495 (0.00%)  
# events     1     0  
Respiratory, thoracic and mediastinal disorders      
Exacerbation of asthma      
# participants affected / at risk     1/1484 (0.07%)     0/1495 (0.00%)  
# events     1     0  
Pleural effusion      
# participants affected / at risk     1/1484 (0.07%)     0/1495 (0.00%)  
# events     1     0  
Respiratory distress      
# participants affected / at risk     1/1484 (0.07%)     0/1495 (0.00%)  
# events     1     0  
Vascular disorders      
Hypertension      
# participants affected / at risk     1/1484 (0.07%)     0/1495 (0.00%)  
# events     1     0  




  Other Adverse Events
  Hide Other Adverse Events

Time Frame No text entered.
Additional Description No text entered.

Frequency Threshold
Threshold above which other adverse events are reported   5%  

Reporting Groups
  Description
Trivalent MRKAd5 HIV-1 Gag/Pol/Nef Participants randomized to receive three 1.0-ml intramuscular (IM) injections of Merck Trivalent Adenovirus Serotype 5 HIV-1 gag/pol/nef (MRKAd5 HIV-1 gag/pol/nef) Vaccine at a dose of 1.5x10^10 adenovirus genomes (Ad vg) per dose at Day 1, Week 4, and Week 26.
Placebo Participants randomized to receive three 1.0-ml intramuscular (IM) injections of placebo to MRKAd5 HIV-1 gag/pol/nef at Day 1, Week 4, and Week 26.

Other Adverse Events
    Trivalent MRKAd5 HIV-1 Gag/Pol/Nef     Placebo  
Total, other (not including serious) adverse events      
# participants affected / at risk     1221/1484     946/1495  
Gastrointestinal disorders      
Diarrhoea      
# participants affected / at risk     156/1484 (10.51%)     148/1495 (9.90%)  
# events     195     182  
Nausea      
# participants affected / at risk     94/1484 (6.33%)     75/1495 (5.02%)  
# events     114     87  
General disorders      
Fatigue      
# participants affected / at risk     170/1484 (11.46%)     120/1495 (8.03%)  
# events     218     149  
Fever      
# participants affected / at risk     376/1484 (25.34%)     309/1495 (20.67%)  
# events     631     548  
General body pain      
# participants affected / at risk     76/1484 (5.12%)     23/1495 (1.54%)  
# events     98     26  
Injection site erythema      
# participants affected / at risk     317/1484 (21.36%)     143/1495 (9.57%)  
# events     448     197  
Injection site pain      
# participants affected / at risk     961/1484 (64.76%)     475/1495 (31.77%)  
# events     1862     702  
Injection site swelling      
# participants affected / at risk     337/1484 (22.71%)     115/1495 (7.69%)  
# events     511     149  
Injection site tenderness      
# participants affected / at risk     271/1484 (18.26%)     81/1495 (5.42%)  
# events     374     92  
Nervous system disorders      
Headache      
# participants affected / at risk     461/1484 (31.06%)     394/1495 (26.35%)  
# events     734     631  
Respiratory, thoracic and mediastinal disorders      
Sore throat      
# participants affected / at risk     83/1484 (5.59%)     83/1495 (5.55%)  
# events     96     90  



  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
The DSMB (Data & Safety Monitoring Board) reviewed interim data which demonstrated that the investigational vaccine was not effective, and all vaccinations were halted. Long term follow up was available for participants in V520-030.


  More Information